Impact of Preoperative Suspension of Antiplatelet Therapy on Thrombotic Events Following Minimally Invasive Surgery for Abdominopelvic Cancer

Overview

This study investigates the effects of preoperative discontinuation versus maintenance of P2Y12 inhibitors on thrombotic complications in patients undergoing minimally invasive surgery for abdominopelvic cancer. Findings suggest that maintaining antiplatelet therapy may reduce thrombotic events without significantly increasing hemorrhagic complications.

Background

Minimally invasive surgery (MIS) is increasingly used for treating abdominopelvic cancers due to its benefits in bleeding control. Patients with a history of arterial thrombotic disease often require antiplatelet therapy, which poses a challenge in managing bleeding and thrombotic risks during surgery. Current guidelines recommend specific preoperative discontinuation periods for P2Y12 inhibitors, but the optimal management strategy remains unclear.

Data Highlights

No numerical data was provided in the source material.

Key Findings

• Preoperative discontinuation of P2Y12 inhibitors may increase the risk of thrombotic events post-surgery.
• Maintaining antiplatelet therapy during minimally invasive surgery may not significantly increase hemorrhagic complications.
• Current guidelines suggest a 5-7 day discontinuation period for P2Y12 inhibitors before high-bleeding-risk surgeries.
• Patients with a history of arterial thrombotic disease are at heightened risk for complications during surgery.
• Bridging therapy with aspirin during surgery is recommended for high thrombotic risk patients.

Clinical Implications

Clinicians should carefully evaluate the risks and benefits of continuing P2Y12 inhibitors in patients undergoing minimally invasive surgery for abdominopelvic cancer. Maintaining antiplatelet therapy may be beneficial in reducing thrombotic events, but careful monitoring for bleeding complications is essential.

Conclusion

The study highlights the need for further research to establish definitive guidelines for managing antiplatelet therapy in patients undergoing minimally invasive surgery. Balancing thrombotic and hemorrhagic risks is crucial for optimal patient outcomes.

References

1. Author(s)/Org, Source, Year -- Title
2. Clinical Research in Cardiology — Preoperative Dual Antiplatelet Therapy with Aspirin and Ticagrelor in Acute Coronary Syndrome Patients Undergoing Emergency Aortocoronary Bypass Surgery
3. Journal of Gastrointestinal Surgery — Impact of Oral Anticoagulant Use on Surgical Outcomes in Patients Facing High-Risk Abdominal Emergencies
4. Surgical Endoscopy — Post-Polypectomy Bleeding Risk in Patients Undergoing Single Antiplatelet Therapy: A Systematic Review and Meta-Analysis
5. Clinical Research in Cardiology — Management of Antiplatelet Therapy in Acute Myocardial Infarction with Cardiogenic Shock Complications
6. 2024 ESC Guidelines for CV Assessment of Noncardiac Surgery: Key Points - American College of Cardiology
7. ACC/AHA Task Force on Clinical Practice Guidelines
8. ASSURE DES: Continuing vs. Interrupting Aspirin Therapy Before Noncardiac Surgery in Patients With DES - American College of Cardiology
9. Perioperative Ischemic Evaluation 2 - American College of Cardiology
10. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events - PMC
11. Comparative analysis of perioperative outcomes in obese patients undergoing robot-assisted radical prostatectomy (RARP) versus open radical prostatectomy (ORP): a systematic review and meta-analysis - PubMed
12. Association between preoperative interruption of antiplatelet therapy and postoperative thrombotic risk after minimally invasive surgery for abdominopelvic cancer in patients treated with P2Y12 inhibitors - PMC